Vaccine appears to pre-empt cervical cancer
4/7/2005 Rita Rubin USA Today (www.usatoday.com) A vaccine against the virus that causes cervical cancer and genital warts cut long-lasting infection by 90%, according to a pilot study out Wednesday. Study co-author Eliav Barr of Merck Research Laboratories says his company expects to apply to the Food and Drug Administration late this year for permission to sell the vaccine, which would be the first against cancer. Merck is now testing the vaccine in more than 25,000 women and children, up to one-third of them in the USA, in an expanded trial whose findings will be submitted to the FDA, Barr says. Up to 70% of sexually active women will become infected with human papillomavirus, or HPV, during their lifetime, Barr and his collaborators write in an article posted online by The Lancet Oncology, a British medical journal. More than 90% of cases clear up on their own. More than 35 types of HPV infect the genital tract, but four dominate, according to the article, the first about a vaccine against all four dominant types. Two types, 16 and 18, are linked to 70% of cases of cervical cancer, diagnosed in 470,000 women worldwide each year but rare in the U.S., thanks to widespread screening. These types are also linked to less common cancers: About 80% of cancers of the anus or vulva are associated with HPV 16, and about half of penile cancers are linked to either 16 or 18, says Luisa Villa, lead study author and biologist with the [...]